146 related articles for article (PubMed ID: 38169017)
1. First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity.
Borazanci E; Saluja A; Gockerman J; Velagapudi M; Korn R; Von Hoff D; Greeno E
Oncologist; 2024 Feb; 29(2):132-141. PubMed ID: 38169017
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer.
Arora N; Alsaied O; Dauer P; Majumder K; Modi S; Giri B; Dudeja V; Banerjee S; Von Hoff D; Saluja A
PLoS One; 2017; 12(2):e0171827. PubMed ID: 28192510
[TBL] [Abstract][Full Text] [Related]
3. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
Isharwal S; Modi S; Arora N; Uhlrich C; Giri B; Barlass U; Soubra A; Chugh R; Dehm SM; Dudeja V; Saluja A; Banerjee S; Konety B
Prostate; 2017 May; 77(6):584-596. PubMed ID: 28144973
[TBL] [Abstract][Full Text] [Related]
4. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.
Modi S; Kir D; Giri B; Majumder K; Arora N; Dudeja V; Banerjee S; Saluja AK
J Gastrointest Surg; 2016 Jan; 20(1):13-23; discussion 23-4. PubMed ID: 26503259
[TBL] [Abstract][Full Text] [Related]
5. Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F.
Oliveira A; Beyer G; Chugh R; Skube SJ; Majumder K; Banerjee S; Sangwan V; Li L; Dawra R; Subramanian S; Saluja A; Dudeja V
Lab Invest; 2015 Jun; 95(6):648-659. PubMed ID: 25893635
[TBL] [Abstract][Full Text] [Related]
6. Minnelide exhibits antileukemic activity by targeting the Ars2/miR-190a-3p axis.
Yuan L; Jiang X; Jia G; Li Z; Wang M; Hu S; Yang J; Liang F; Zhang F; Gao L; Gao N
Phytomedicine; 2024 Jul; 130():155724. PubMed ID: 38759317
[TBL] [Abstract][Full Text] [Related]
7. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer.
Modi S; Giri B; Gupta VK; Lavania S; Sethi V; Sharma NS; Pandey S; Vickers S; Dudeja V; Saluja AK
Cancer Lett; 2022 Jul; 537():215591. PubMed ID: 35398530
[TBL] [Abstract][Full Text] [Related]
8. Triptolide and Its Derivatives as Cancer Therapies.
Noel P; Von Hoff DD; Saluja AK; Velagapudi M; Borazanci E; Han H
Trends Pharmacol Sci; 2019 May; 40(5):327-341. PubMed ID: 30975442
[TBL] [Abstract][Full Text] [Related]
9. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer.
Banerjee S; Modi S; McGinn O; Zhao X; Dudeja V; Ramakrishnan S; Saluja AK
Clin Cancer Res; 2016 Jan; 22(2):415-25. PubMed ID: 26405195
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.
Giri B; Gupta VK; Yaffe B; Modi S; Roy P; Sethi V; Lavania SP; Vickers SM; Dudeja V; Banerjee S; Watts J; Saluja A
J Transl Med; 2019 May; 17(1):163. PubMed ID: 31109340
[TBL] [Abstract][Full Text] [Related]
11. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.
Chugh R; Sangwan V; Patil SP; Dudeja V; Dawra RK; Banerjee S; Schumacher RJ; Blazar BR; Georg GI; Vickers SM; Saluja AK
Sci Transl Med; 2012 Oct; 4(156):156ra139. PubMed ID: 23076356
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.
Rivard C; Geller M; Schnettler E; Saluja M; Vogel RI; Saluja A; Ramakrishnan S
Gynecol Oncol; 2014 Nov; 135(2):318-24. PubMed ID: 25172764
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial.
Lim SH; Saluja A; Vickers S; Hong JY; Kim ST; Lavania S; Pandey S; Gupta VK; Velagapudi MR; Lee J
Cancer Lett; 2024 Jun; 597():217041. PubMed ID: 38866072
[TBL] [Abstract][Full Text] [Related]
14. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
15. Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo.
Rousalova I; Banerjee S; Sangwan V; Evenson K; McCauley JA; Kratzke R; Vickers SM; Saluja A; D'Cunha J
PLoS One; 2013; 8(10):e77411. PubMed ID: 24143232
[TBL] [Abstract][Full Text] [Related]
16. Minnelide, a novel drug for pancreatic and liver cancer.
Banerjee S; Saluja A
Pancreatology; 2015 Jul; 15(4 Suppl):S39-43. PubMed ID: 26122306
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
[TBL] [Abstract][Full Text] [Related]
18. Potentially reversible acute cerebellar toxicity associated with Minnelide.
Khanipour Roshan S; Spano AD; McKinney AM; Nascene DR
Neuroradiology; 2017 Apr; 59(4):419-421. PubMed ID: 28303374
[TBL] [Abstract][Full Text] [Related]
19. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.
Caicedo-Granados E; Lin R; Fujisawa C; Yueh B; Sangwan V; Saluja A
Oral Oncol; 2014 Dec; 50(12):1149-56. PubMed ID: 25311433
[TBL] [Abstract][Full Text] [Related]
20. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.
Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S
Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
